Home Cart Sign in  
Chemical Structure| 113558-15-9 Chemical Structure| 113558-15-9

Structure of Baohuoside I
CAS No.: 113558-15-9

Chemical Structure| 113558-15-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Baohuoside I, a flavonoid, acts as an apoptosis inducer and a down-regulator of durvivin and cyclin D1 expression. It is used as an anti-cancer agent and can be isolated and purified from the roots of epimedium brevicornu Maxim.

Synonyms: Icariin-II; Icariside-II

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Baohuoside I

CAS No. :113558-15-9
Formula : C27H30O10
M.W : 514.52
SMILES Code : OC1=CC(O)=C(C/C=C(C)/C)C(OC(C2=CC=C(OC)C=C2)=C3O[C@H]4[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O4)=C1C3=O
Synonyms :
Icariin-II; Icariside-II
MDL No. :MFCD15071140
InChI Key :NGMYNFJANBHLKA-LVKFHIPRSA-N
Pubchem ID :5488822

Safety of Baohuoside I

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Baohuoside I

GPCR

Isoform Comparison

Biological Activity

Description
Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 cells 100μg/mL 48 h H-EV-ApoBHS treated with Baohuoside I reduced the invasion and apoptosis resistance of MDA-MB-231 cells. PMC11270583
Raw264.7 macrophages 100μg/mL 48 h EV-Apo significantly induced M2 polarization of Raw264.7 macrophages, while EV-ApoBHS treated with Baohuoside I reduced this effect. PMC11270583
4T1 cells 1.25-5μM 48 h Baohuoside I significantly enhanced the inhibitory effects of paclitaxel on the proliferation and colony formation abilities of 4T1 cells and reduced paclitaxel-induced apoptosis resistance. PMC11270583
Rat liver microsomes (RLMs) 1, 2.5, 5, 10, 25, 50, 100, 200, 400 μM 30 min To evaluate the inhibitory effect of Baohuoside I on tofacitinib metabolism, the results showed that Baohuoside I has a clear in vitro inhibitory effect on tofacitinib, and its inhibition mechanism is a mixture of non-competitive and competitive inhibition. PMC10980839
Bone marrow monocytes (BMMs) 0.01, 0.1, 1 μM Evaluate the effect of Baohuoside I on RANKL-induced osteoclast differentiation, results showed that Baohuoside I inhibited osteoclast formation in a dose-dependent manner. PMC9092047
Bone marrow monocytes (BMMs) 0.01, 0.1, 1 μM 7 days Evaluate the cytotoxicity of Baohuoside I on BMMs, results showed that different concentrations of Baohuoside I had no cytotoxic effect on BMMs. PMC9092047
Human multiple myeloma cell lines (RPMI8226 and U266) 50 μM 3 h BI inhibited VEGF expression by binding and activating PPARγ PMC8948427
Human umbilical vein endothelial cells (HUVECs) 10 μM 48 h BI-treated MM cell supernatants significantly inhibited the growth and tube formation of HUVECs PMC8948427

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice 4T1-Luc xenograft model Intraperitoneal injection 20mg/kg Once daily Baohuoside I combined with paclitaxel significantly inhibited breast cancer growth and lung metastasis, reduced tumor-associated macrophage infiltration and PD-L1 expression. PMC11270583
Sprague-Dawley rats Drug-drug interaction model Oral 20 mg/kg Single-dose group: administered once on the 7th day; multi-dose group: administered once daily for 7 consecutive days To investigate the effect of Baohuoside I on the pharmacokinetics of tofacitinib, the results showed that oral administration of Baohuoside I increased the AUC of tofacitinib, prolonged Tmax, and decreased the CL of the drug. PMC10980839
C57/BL6 mice Ovariectomy-induced osteoporosis model Intraperitoneal injection 10 mg/kg Administered every other day for 6 weeks Evaluate the protective effect of Baohuoside I on ovariectomy-induced bone loss, results showed that Baohuoside I prevented bone loss by interrupting osteoclast formation and activity. PMC9092047
BALB/c nude mice Human myeloma xenograft model Subcutaneous injection 25 mg/kg Injected every other day for 33 days BI significantly inhibited tumor growth and angiogenesis, reduced VEGF expression and microvessel density PMC8948427

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.94mL

0.39mL

0.19mL

9.72mL

1.94mL

0.97mL

19.44mL

3.89mL

1.94mL

References

 

Historical Records

Categories